Icon

Braftovi - (75 mg ; Capsule)

Encorafenib Array BioPharma
75 mg ; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
BRAFTOVI is a kinase inhibitor indicated, in combination with Binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Yes
***** *** * *** ********* *** ******* ** *** **** *** *******. ***** *** *** ***** ** ** *********; ***** ******** **** ***** **** ************ ** ****** '***. *** ********** *** ******** (*******) ***** ***** ******* *** ****-** ** * ******* **** ************* (***** ***) *.*.*. '***. ***** *** ***** ****-** **** * ***** ******* - '***, '***, '*** (*** ******** ** ****) *** *** *** ********* *** *** ****. ** ** *** ******* ***** ***** * **** *** **** *** ********* *******. ****** (******) ******** ********* ******** *** *** *** *********. ** ****** **** ***** * **** ***.
Braftovi Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
***** ****** **** *** **** *** **** *** **** *** *** ********* ********* ** ***** *** **** *** **** *** *** ********* **** *** **** *** **** *** *** *********
****** **** *** **** *** **** *** **** *** *** ********* ***** *** **** *** **** *** *** ********* **** *** **** *** **** *** ***** ***
**** ******* **** *** ******* **** *** ******* **** *** ******* **** *** *** ********* ******* ***** *** ******* **** *** ******* **** *** *** ********* ******* **** *** ******* **** *** ******* **** *** ******* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ ********* *** **, **** ********* ***** ******* *** **** ** *** **, ****
****** *** \ ********* -**- *** ********* ********* ******** ** *** **, ****
**** *** \ ********* -**- *** ********* ********* ******** ** *** **, ****
  1. *** **, **** : * ****-** ** ***** *** ***** *** ***** *** *********.
  2. *** *, **** : ***** ******** ***** ******** ** *** ****-** ****** **** ******* '***, '***, '*** *** '***
  3. *** **, **** : ***** ******** **** ***** **** ************ ** ****** '*** (*** **, ****)
  4. *** **, **** : ***** ******** ********* ********** ***** ***** ******* *** ****-**, ******* *** ****** '***.
  5. *** **, **** : ****** ******** ********* ******** *** *** *** *********. ** ****** **** ***** * **** ***.
  6. *** **, **** : ****** ***** **** ** '*** *** '*** *******, ****** *** '*** *** '*** *******, *** ***** **** *** ** *** ****.
  7. *** *, **** : **** *** ******** ********* ******** *** *** *** *********. ** ****** **** ***** * **** *** **** **** ****** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.